Peter David Byeff MD
Breast Cancer, Gastrointestinal Cancer, Head & Neck Cancer, Hematologic Oncology
Physician
Join to View Full Profile
55 Meriden AveSte 1ASouthington, CT 06489
Phone+1 860-621-9316
Fax+1 860-620-5526
Dr. Byeff is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1981
MedStar Georgetown University Hospital1977
MedStar Health Georgetown University/Georgetown HospitalInternship, Internal Medicine, 1974 - 1975
Johns Hopkins University School of MedicineClass of 1974
Certifications & Licensure
NY State Medical License 1977 - Present
CT State Medical License 1982 - 2026
FL State Medical License 1982 - 1985
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Connecticut Top Doctor Connecticut Magazine, 2021-2022
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2011, 2013-2017
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2011, 2013-2017
Clinical Trials
- BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Nov 01
- Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer Start of enrollment: 2008 Oct 07
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- 11 citationsHealth-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethas...Katja Weisel, Meletios A. Dimopoulos, Philippe Moreau, Münci Yağcı, Alessandra Larocca
Leukemia & Lymphoma. 2020-04-09 - 56 citationsMycobacterium haemophilum Infection in Immunocompromised Patients: Case Report and Review of the LiteratureMar Kristjansson, Virginia M. Bieluch, Peter D. Byeff
Reviews of Infectious Diseases. 1991-09-01 - 19 citationsPhenotypic heterogeneity of human T-cell malignancies: Demonstration by monoclonal antibodies and cytochemical markersDaniel M. Knowles, James P. Halper, Genevieve A. Machin, Peter Byeff, Roland Mertelsman
American Journal of Hematology. 1982-05-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
